Edition:
India

Adaptimmune Therapeutics PLC (ADAP.OQ)

ADAP.OQ on NASDAQ Stock Exchange Global Select Market

7.89USD
21 Nov 2017
Change (% chg)

-- (--)
Prev Close
$7.89
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
68,572
52-wk High
$9.22
52-wk Low
$3.76

Revenue & Earnings Per Share

    Revenue* Earnings Per Share**
FY 2017 Jun '17 3.52 -0.036
Mar '17 2.86 -0.051
FY 2016 Dec '16 8.54 -0.036
Sep '16 2.42 -0.044
Jun '16 0.33 -0.052
Mar '16 2.92 -0.037
FY 2015 Dec '15 2.78 -0.053
Mar '15 2.73 -0.046
Dec
 
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars

Consensus Estimates Analysis

  # of Estimates Mean High Low 1 Year Ago
SALES (in millions)
Quarter Ending Dec-17 7 7.91 17.44 0.00 10.68
Quarter Ending Mar-18 5 11.43 22.00 4.00 11.47
Year Ending Dec-17 7 41.50 51.00 33.60 22.49
Year Ending Dec-18 7 52.40 88.00 32.50 37.69
Earnings (per share)
Quarter Ending Dec-17 6 -0.23 -0.12 -0.32 -0.34
Quarter Ending Mar-18 5 -0.21 -0.08 -0.25 -0.23
Year Ending Dec-17 6 -0.75 -0.61 -0.94 -1.17
Year Ending Dec-18 6 -0.81 -0.39 -1.29 -1.12
Sales and Profit Figures in US Dollar (USD);

Valuation Ratios

Dividends

Growth Rates

Financial Strength

Profitability Ratios

Efficiency

Management Effectiveness

  1 Year 3 Year 5 Year
Sales % -- -- --
EPS (TTM) % -- -- --
Dividend % -- -- --
Note: Units in Millions of US Dollars

Performance for Adaptimmune Therapeutics PLC

Period %
Actual
% vs.
S&P 500
Rank In
Industry
Industry
Rank
4 Week -8.62 -11.77 21 --
13 Week 66.87 58.74 94 --
26 Week 43.16 32.28 84 --
52 Week 20.18 1.86 66 --
YTD 101.48 76.94 88 --
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.

Institutional Holders

% Shares Owned: 10.25%
# of Holders: 67
Total Shares Held: 57,620,832
3 Mo. Net Change: 2,664,498
# New Positions: 16
# Closed Positions: 6
# Increased Positions: 38
# Reduced Positions: 20
# Net Buyers: 18
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.